Phase 3Enrolling by invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)
- Sponsor
- United Therapeutics (Industry)
- Enrolment
- 1,850 planned
- Conditions
- Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Progressive Pulmonary Fibrosis
- Interventions
- Inhaled Treprostinil; Treprostinil Ultrasonic Nebulizer
- Ages
- adults, older adults
- Registry
- NCT04905693
Full record on ClinicalTrials.gov
From the registry
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
Primary outcomes
- Long-term safety and tolerability of inhaled treprostinil in subjects with IPF or PPF
History
Primary completion expected
Last registry update
Started
Registered